Percutaneous Coronary Intervention Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Influence of COVID-19 pandemic in India on coronary artery disease clinical presentation, angiography, interventions and in-hospital outcomes: a single centre prospective registry-based observational study
Conclusions In-hospital mortality among patients with CAD undergoing PCI was significantly higher in the second year of the COVID-19 pandemic in India and could be one of the reasons for excess deaths in the country. These patients had more severe CAD, lower LVEF, and more vasopressor and mechanical support and duration of hospitalisation. (Source: BMJ Open)
Source: BMJ Open - March 29, 2024 Category: General Medicine Authors: Gupta, R., Sharma, K., Khedar, R. S., Sharma, S. K., Makkar, J. S., Natani, V., Bana, A., Sharma, S. Tags: Open access, Cardiovascular medicine Source Type: research

Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long?
Med Clin North Am. 2024 May;108(3):539-551. doi: 10.1016/j.mcna.2023.12.003. Epub 2024 Jan 9.ABSTRACTDual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is recommended for at least 6 and 12 months following percutaneous coronary intervention with drug-eluting stents among patients with stable ischemic heart disease and acute coronary syndrome, respectively. Additional exposure to antiplatelet therapy reduces ischemic events but also increases bleeding risk. Conversely, shorter durations of DAPT are preferred among those at high bleeding risk. Hence, decisions surrounding duration of DAPT after revasculariza...
Source: The Medical Clinics of North America - March 28, 2024 Category: General Medicine Authors: Khawaja Hassan Akhtar Usman Baber Source Type: research

Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention
ConclusionAmong adults who underwent first-ever PCI for ACS, ticagrelor use in the DAPT was associated with a lower risk of MOF compared with clopidogrel. Our results support the use of ticagrelor in the DAPT from the perspective of bone health. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 27, 2024 Category: Endocrinology Source Type: research

Clinical Impacts of Urinary Neutrophil Gelatinase-Associated Lipocalin in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
CONCLUSIONS: Urinary NGAL could be a novel and informative biomarker for predicting subsequent renal and cardiovascular events in patients with CKD undergoing elective PCI.PMID:38538331 | DOI:10.1253/circj.CJ-24-0060 (Source: Circulation Journal)
Source: Circulation Journal - March 27, 2024 Category: Cardiology Authors: Yuta Ozaki Yusuke Uemura Akihito Tanaka Shogo Yamaguchi Takashi Okajima Takayuki Mitsuda Shinji Ishikawa Kenji Takemoto Toyoaki Murohara Masato Watarai Source Type: research

It Is Time to Overcome the “One-Size-Fits-All” Approach in Chronic Coronary Syndrome?
Chronic coronary syndrome (CCS) refers to a wide spectrum of clinical conditions characterized by clinically stable progression of coronary artery disease (CAD).1 Current guidelines recommend the administration of dual antiplatelet therapy (DAPT) with cardioaspirin and clopidogrel for 6 months for patients who underwent elective percutaneous coronary intervention (PCI).1 However, patients with CCS represent a heterogeneous population, and the type and duration of DAPT can be modulated weighting the individual ischemic and hemorrhagic risks. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - March 27, 2024 Category: Cardiology Authors: Giampaolo Niccoli, Filippo Luca Gurgoglione Tags: Editorial Source Type: research

It's time to overcome the "One-Size-Fits-All" approach in chronic coronary syndrome?
Chronic coronary syndrome (CCS) refers to a wide spectrum of clinical conditions characterized by clinically stable progression of coronary artery disease (CAD) [1]. Current guidelines recommend the administration of dual antiplatelet therapy (DAPT) with cardioaspirin and clopidogrel for 6 months for patients undergoing elective percutaneous coronary intervention (PCI) [1]. However, patients with CCS represent a heterogeneous population and the type and duration of DAPT can be modulated weighting the individual ischemic and hemorrhagic risks [1]. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - March 27, 2024 Category: Cardiology Authors: Giampaolo Niccoli, Filippo Luca Gurgoglione Tags: Editorial Source Type: research

PRECISE-DAPT, ARC-HBR or Simplified Clinical Evaluation for the Prediction of Major Bleeding after Percutaneous Coronary Intervention in Elderly Patients
Elderly patients have been remarkably under-represented in bleeding risk cohorts. Thus, the PRECISE-DAPT and ARC-HBR scores are not validated in older adults. Therefore, we sought to evaluate the PRECISE-DAPT and ARC-HBR scores in an exclusively elderly population and furthermore assess the prognostic value of a truly simplified clinical evaluation (SCE), consisting of only 3 binary clinical variables (hemoglobin (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - March 27, 2024 Category: Cardiology Authors: Alexander Marschall, Juan Duarte Torres, Bel én Biscotti Rodíl, Inés Gómez Sánchez, Elena Basabe Velasco, Carmen Ramos Alejos-Pita, Edurne López Soberón, Alfonso Suárez Cuervo, Salvador Álvarez Antón, Jose María de la Torre Hernández, David Ma Source Type: research

Emergent Coronary Thrombectomy for Acute Myocardial Infarction Immediately Following Craniotomy with Tumor Resection
AbstractThe management of perioperative acute myocardial infarction (AMI) following oncologic neurosurgery requires balancing competing risks of myocardial ischemia and postoperative bleeding. There are limited human data to establish the safest timing of antiplatelet or anticoagulation therapy following neurosurgical procedures. For patients with malignancy experiencing AMI in the acute postoperative period, staged percutaneous coronary intervention (PCI) with upfront coronary aspiration thrombectomy followed by delayed completion PCI may offer an opportunity for myocardial salvage while minimizing postoperative bleeding ...
Source: Cardiology and Therapy - March 27, 2024 Category: Cardiology Source Type: research

PRECISE-DAPT, ARC-HBR, or Simplified Clinical Evaluation for the Prediction of Major Bleeding After Percutaneous Coronary Intervention in Elderly Patients
Elderly patients have been remarkably underrepresented in bleeding risk cohorts. Thus, the PRECISE-DAPT and Academic Research Consortium for High Bleeding Risk (ARC-HBR) scores are not validated in older adults. Therefore, we sought to evaluate the PRECISE-DAPT and ARC-HBR scores in an exclusively elderly population and assess the prognostic value of a truly simplified clinical evaluation (SCE), consisting of only 3 binary clinical variables (hemoglobin (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - March 27, 2024 Category: Cardiology Authors: Alexander Felix Marschall, Juan Duarte Torres, Bel én Biscotti Rodíl, Inés Gómez Sánchez, Elena Basabe Velasco, Carmen Ramos Alejos-Pita, Edurne López Soberón, Alfonso Suárez Cuervo, Salvador Álvarez Antón, Jose María de la Torre Hernández, Da Source Type: research

The American Heart Association's Centennial and Percutaneous Coronary Intervention's Semi-Centennial
Circulation. 2024 Mar 26;149(13):973-978. doi: 10.1161/CIRCULATIONAHA.123.064461. Epub 2024 Mar 25.NO ABSTRACTPMID:38527128 | DOI:10.1161/CIRCULATIONAHA.123.064461 (Source: Circulation)
Source: Circulation - March 25, 2024 Category: Cardiology Authors: Patrick W Serruys Pruthvi C Revaiah Source Type: research

Comprehensive effect of Naoxintong capsule combined with Western medicine on coronary heart disease after percutaneous coronary intervention: a meta-analysis
Conclusion:A combination of NXT and WM can improve clinical outcomes in patients undergoing PCI. However, further studies are needed to confirm the reliability and safety of this combined treatment approach.Systematic Review Registration:PROSPERO, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=369174, Identifier CRD42022369174. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - March 25, 2024 Category: Drugs & Pharmacology Source Type: research